It has been shown that high serum IL‐7 levels may help to distinguish patients with prostate cancer from those with benign prostate hypertrophy [21], unfortunately, it does not seem to be the case in our study, serum IL‐7 could not distinguish MPM from BPE. This evidence concerns the gene IL7 and benign prostatic hyperplasia.